Hormosan Pharma Gesellschaft mit beschränkter Haftung

Hormosan Pharma GmbH distributes prescription medicines primarily to the pharmaceutical wholesale market and recorded revenue of EUR 55.1 million in the 2024/25 fiscal year. The product portfolio comprises 59 products, of which 51 are generics, and focuses on indications such as severe headaches (notably cluster headaches and severe migraine), pain therapy, sexual health, asthma, COPD and rare neurological diseases. The company does not conduct its own product development; the portfolio is based on purchased licenses and the takeover of completed product developments or already granted marketing authorizations. Hormosan has been active in the German market since 1968 and has been part of the Lupin group via Nanomi B.V. since mid-2008, with Lupin Ltd. as the parent company.